# US 2013/0157358 A1 · Method for neuroepithelial cells differentiation from pluripotent stem cells and medium using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157358 A1
- Document ID: US20130157358A1
- Status: Published application
- Kind: A1
- Application number: 13/485,914
- Filed: 2012-05-31
- Published: 2013-06-20
- Earliest claimed: 2011-12-14
- Inventors: Hong-Lin Su; Sheng-Mei Chen
- Web page: https://patentgrep.com/patent/US20130157358A1

## CPC

- C12N 5/0623: {Stem cells}
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2506/02: from embryonic cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention discloses a neural induction medium comprising Wnt-signal agonist, TGFβ-signal inhibitor and FGF-signal agonist for inducing neural differentiation. The neural induction medium used in a culture system is capable for inducing the neural differentiation of stem cells into neuroepithelial cells which are useful for the clinical applications. Therein, the neuroepithelial cells can further differentiate into mature neurons for the practical applications including regeneration medicine and drug discovery for neural disorders.

## Claims

### Claim 1

A neural induction medium comprises Wnt-signal agonist, TGFβ-signal inhibitor and FGF-signal agonist.

### Claim 2 (depends on 1)

The neural induction medium of claim 1, wherein the Wnt-signal agonist is selected from the group consisting of Wnt ligands and GFK-3β inhibitor (glycogen synthase kinase 3β inhibitor) BIO (6-bromoindirubin-3′-oxime).

### Claim 3 (depends on 1)

The neural induction medium of claim 1, wherein the Wnt-signal agonist is GFK-3β inhibitor BIO with the working concentration between 0.05 μM to 50 μM.

### Claim 4 (depends on 2)

The neural induction medium of claim 2, wherein the Wnt-signal agonist is GFK-3β inhibitor BIO with the working concentration between 0.05 μM to 50 μM.

### Claim 5 (depends on 1)

The neural induction medium of claim 1, wherein the TGFβ-signal inhibitor is selected from the group consisting of bone morphogenetic protein inhibitor (BMP inhibitor), Chordin, Noggin, Dorsomorphin, Smad1 inhibitor, Activin/Nodal receptor inhibitor SB431542, and Smad2/3-inhibitor.

### Claim 6 (depends on 1)

The neural induction medium of claim 1, wherein the TGFβ-signal inhibitor is Activin/Nodal receptor inhibitor SB431542 with working concentration between 1 μM to 100 μM.

### Claim 7 (depends on 5)

The neural induction medium of claim 5, wherein the TGFβ-signal inhibitor is Activin/Nodal receptor inhibitor SB431542 with working concentration between 1 μM to 100 μM.

### Claim 8 (depends on 1)

The neural induction medium of claim 1, wherein the FGF-signal agonist is selected from the group consisting of FGF2, FGFR ligand, ERK (extracellular signal-related kinase) activator, JNK (c-jun N-terminal kinase kinase) activator and PI3K (phosphoinosital-3 kinase) activator.

### Claim 9 (depends on 1)

The neural induction medium of claim 1, wherein the FGF-signal agonist is FGF2 with working concentration between 1 ng/ml to 10 ng/ml.

### Claim 10 (depends on 8)

The neural induction medium of claim 8, wherein the FGF-signal agonist is FGF2 with working concentration between 1 ng/ml to 10 ng/ml.

### Claim 11 (depends on 1)

A use of the neural induction medium of claim 1 in inducing the neural differentiation of pluripotent stem cells into neuroepithelial cells.

### Claim 12 (depends on 1, 10)

A method for neuroepithelial cells differentiation from pluripotent stem cells comprising steps of:
(a) culturing a pluripotent stem cell into an embryoid body by suspension culture;
(b) culturing the embryoid body in a first neural induction medium for generating neuroepithelial cells, wherein the first neural induction medium is selected from the group consisting of claim 1 to claim 10.

### Claim 13 (depends on 12)

The method for neuroepithelial cells differentiation from pluripotent stem cells of claim 12, further including a step (c) below after step (b):
(c) substituting the first neural induction medium to a secondary neural induction medium for promoting the further differentiation.

### Claim 14 (depends on 12)

The method for neuroepithelial cells differentiation from pluripotent stem cells of claim 12, wherein the pluripotent stem cell of step (a) is selected from a group consisting of human embryonic stem cell and iPSC (induced pluripotent stem cell).

### Claim 15 (depends on 13)

The method for neuroepithelial cells differentiation from pluripotent stem cells of claim 13, wherein the pluripotent stem cell of step (a) is selected from a group consisting of human embryonic stem cell and iPSC (induced pluripotent stem cell).
